Cargando…

A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic

BACKGROUND: Some metabolic disorders, including abnormal calcium metabolism, can develop and worsen parkinsonism. However, whether hyperparathyroidism can cause parkinsonism remains controversial. CASE PRESENTATION: An 83-year-old woman with a history of right thalamic hemorrhage and drug-induced pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohya, Yuichiro, Osaki, Masato, Sakai, Shota, Kimura, Shunsuke, Yasuda, Chiharu, Ago, Tetsuro, Kitazono, Takanari, Arakawa, Shuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937038/
https://www.ncbi.nlm.nih.gov/pubmed/29734949
http://dx.doi.org/10.1186/s12883-018-1067-7
_version_ 1783320564668039168
author Ohya, Yuichiro
Osaki, Masato
Sakai, Shota
Kimura, Shunsuke
Yasuda, Chiharu
Ago, Tetsuro
Kitazono, Takanari
Arakawa, Shuji
author_facet Ohya, Yuichiro
Osaki, Masato
Sakai, Shota
Kimura, Shunsuke
Yasuda, Chiharu
Ago, Tetsuro
Kitazono, Takanari
Arakawa, Shuji
author_sort Ohya, Yuichiro
collection PubMed
description BACKGROUND: Some metabolic disorders, including abnormal calcium metabolism, can develop and worsen parkinsonism. However, whether hyperparathyroidism can cause parkinsonism remains controversial. CASE PRESENTATION: An 83-year-old woman with a history of right thalamic hemorrhage and drug-induced parkinsonism, was admitted due to worsening of parkinsonian symptoms including mask-like face, bradykinesia, freezing of gait, and rigidity. She had been diagnosed with autoimmune hepatitis and was being treated with prednisolone. Examinations revealed hypercalcemia (14.3 mg/dL) with an increased level of intact parathyroid hormone (iPTH) (361 pg/mL). Her symptoms were resistant to some additional anti-parkinsonian drugs; however, cinacalcet hydrochloride, a calcimimetic for the treatment of secondary hyperparathyroidism, normalized levels of serum calcium and iPTH, and remarkably improved her symptoms. CONCLUSIONS: In the present case, we speculate that hypercalcemia probably due to secondary hyperparathyroidism that had developed during steroid therapy deteriorated the parkinsonism.
format Online
Article
Text
id pubmed-5937038
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59370382018-05-14 A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic Ohya, Yuichiro Osaki, Masato Sakai, Shota Kimura, Shunsuke Yasuda, Chiharu Ago, Tetsuro Kitazono, Takanari Arakawa, Shuji BMC Neurol Case Report BACKGROUND: Some metabolic disorders, including abnormal calcium metabolism, can develop and worsen parkinsonism. However, whether hyperparathyroidism can cause parkinsonism remains controversial. CASE PRESENTATION: An 83-year-old woman with a history of right thalamic hemorrhage and drug-induced parkinsonism, was admitted due to worsening of parkinsonian symptoms including mask-like face, bradykinesia, freezing of gait, and rigidity. She had been diagnosed with autoimmune hepatitis and was being treated with prednisolone. Examinations revealed hypercalcemia (14.3 mg/dL) with an increased level of intact parathyroid hormone (iPTH) (361 pg/mL). Her symptoms were resistant to some additional anti-parkinsonian drugs; however, cinacalcet hydrochloride, a calcimimetic for the treatment of secondary hyperparathyroidism, normalized levels of serum calcium and iPTH, and remarkably improved her symptoms. CONCLUSIONS: In the present case, we speculate that hypercalcemia probably due to secondary hyperparathyroidism that had developed during steroid therapy deteriorated the parkinsonism. BioMed Central 2018-05-07 /pmc/articles/PMC5937038/ /pubmed/29734949 http://dx.doi.org/10.1186/s12883-018-1067-7 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Ohya, Yuichiro
Osaki, Masato
Sakai, Shota
Kimura, Shunsuke
Yasuda, Chiharu
Ago, Tetsuro
Kitazono, Takanari
Arakawa, Shuji
A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
title A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
title_full A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
title_fullStr A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
title_full_unstemmed A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
title_short A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
title_sort case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5937038/
https://www.ncbi.nlm.nih.gov/pubmed/29734949
http://dx.doi.org/10.1186/s12883-018-1067-7
work_keys_str_mv AT ohyayuichiro acaseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT osakimasato acaseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT sakaishota acaseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT kimurashunsuke acaseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT yasudachiharu acaseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT agotetsuro acaseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT kitazonotakanari acaseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT arakawashuji acaseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT ohyayuichiro caseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT osakimasato caseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT sakaishota caseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT kimurashunsuke caseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT yasudachiharu caseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT agotetsuro caseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT kitazonotakanari caseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic
AT arakawashuji caseofhyperparathyroidismassociatedparkinsonismsuccessfullytreatedwithcinacalcethydrochlorideacalcimimetic